Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Climate change and housing instability are huge indicators of poor health, said Josh Balloch, vice president of health policy and communications at AllCare Health, a Medicaid insurer in Oregon
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
There is no risk with shorter intervals
Use a 0.3 ml (30-unit) syringe for doses under 25 units whenever possible
A registry check of ClinicalTrials.gov reveals no large, completed, published trials establishing a human safety profile
Understanding reconstitution, calculation methods, and administration techniques supports reliable protocol implementation
